meRfi®-GM
Anti-PD-L1 antibodies / PD-L1 inhibitors
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
undefined…
References (Sources)
- anti-PD1 & anti-PD-L1 checkpoint inhibitors: differences in mechanism of action
- Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancerReview
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsReview
- Patient selection for anti-PD-1/PD-L1 therapy in advanced NSCLC: implications for clinical practice
- SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer
- Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health